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Abstract Ingenol mebutate has recently been approved
by the Federal Drug Administration (USA) as a topical
treatment for actinic keratoses. Herein, we describe the
efficacy of ingenol mebutate for the topical treatment of
squamous cell carcinoma (SCC) using a wild-type mouse
model (SKH1) and the UV-induced mouse SCC cell line,
T7. Daily treatment for 2 days with 0.25 % ingenol
mebutate gel produced a cure rate of 70 %, with 0 % for
placebo gel. Electron microscopy revealed swelling of
cancer cell mitochondria within 1 h, with disruption of the
inner mitochondrial membranes evident at 6 h post treat-
ment. Primary necrosis of cancer cells was clearly evident
by 24 h. Treatment was associated with local haemorrhage
and a prodigious neutrophil infiltrate, with anti-T7 anti-
bodies also detected. This is the first report of the suc-
cessful treatment of SCC tumours with ingenol mebutate
gel in wild-type mice, and supports the view that ingenol
mebutate induces primary necrosis and activates the
immune system.
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Introduction
Cutaneous squamous cell carcinoma (SCC) is the second
most common human cancer after basal cell carcinoma,
with[250,000 cases diagnosed in the USA each year. The
usual treatment options include surgery, curettage and
electrodesiccation, and radiation [2]. Topical imiquimod or
fluorouracil may also be suitable for patients with small
tumours in low-risk locations, who are unwilling or
unsuitable to receive conventional treatments [10].
Following phase III studies [8], topical ingenol mebutate
(ingenol-3-angelate, PEP005) was recently approved by the
Federal Drug Administration (USA) for the treatment of
actinic keratosis, a precursor of SCC. Ingenol mebutate
was derived from the sap of Euphorbia peplus, and in a
phase I/II clinical study, a complete clinical response was
achieved in 2/4 SCCs treated topically with the sap from
this plant [14]. Ingenol mebutate was also effective against
inoculated murine SCC tumours (LK2 and PAM212)
grown in nude mice (Foxn1nu or BALB/cnu/nu) [9, 12], with
haemorrhage [9], neutrophils and antibody-dependent cel-
lular cytotoxicity appearing to be important for relapse-free
cure in these models [4]. In general, mouse studies have
suggested that ingenol mebutate has a dual mechanism of
action against tumours involving initial induction of pri-
mary necrosis [12] followed by immune-mediated clear-
ance of residual tumour cells [17].
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T cell deficient nude mice may not be ideal for testing
treatments for SCCs, as SCCs are believed to be subject to
immune control [20]. This contention may extend to the
testing of ingenol mebutate treatment in nude mice [9, 12],
as there is emerging evidence suggesting cross talk
between neutrophils and T cells [13, 18], with ingenol
mebutate treatment also shown to induce anti-cancer T
cells and antibodies [4, 7]. Here we test ingenol mebutate
in an immunologically intact mouse model, inbred SKH1
mice [5] inoculated with the T7 SCC line, derived from an
SCC induced in these mice by chronic minimally erythe-
mal ultraviolet irradiation [11].
Materials and methods
T7 cell line
T7 was provided by Dr G. Halliday (University of Sydney,
NSW, Australia) and tested negative for mouse hepatitis
virus, minute virus of mice, mouse parvovirus and rotavi-
rus. Cells were maintained as described [11]. Exponentially
growing cultures were trypsinised, washed once in growth
medium, and resuspended in DMEM prior to inoculation.
Electron microscopy of T7 tumours demonstrated the
presence of desmosomes, confirming the epithelial origin
of the T7 line (see Online Resource 1).
Mice, tumour inoculation, treatment and monitoring
Inbred SKH1 hairless (hr/hr) mice (ARC, Perth, Australia)
were bred at QIMR [5]. Mice ([4 weeks old) were inoc-
ulated (5 9 104 T7 cells in 50 ll) by shallow s.c. injection
on the back. Tumours were measured using digital
callipers, and size were expressed as width 9 length.
Tumours were treated topically (on days 4 and 5 post
tumour inoculation) with 30 ll of 0.25 % (w/v) ingenol
mebutate or placebo gel (supplied by LEO Pharma A/S)
using a positive displacement pipette, with the gel then
spread over the tumour site.
Histology and electron microscopy
Histology and electron microscopy were undertaken as
described [4, 12].
Results
Treatment of T7 SCC tumours growing in female mice
with 0.25 % ingenol mebutate (once daily for two days)
resulted in a 70 % cure rate, defined as no visible tumour
after 150 days post treatment initiation (Fig. 1, logrank
test, placebo vs ingenol mebutate, p = 0.0002). When the
ingenol mebutate dose was reduced to 0.1 % in female
mice, tumour growth was delayed significantly by
&10 days (placebo vs ingenol mebutate, p = 0.0006), but
the treatment failed to cure any of the tumours (data not
shown).
Treatment of T7 tumours in male mice with 0.25 %
ingenol mebutate resulted in a cure rate of 30 % (placebo
vs ingenol mebutate p = 0.008, n = 10 per group) (data
not shown). The difference between male and female mice
treated with 0.25 % ingenol mebutate approached signifi-
cance (p = 0.108).
Within hours of ingenol mebutate treatment, clear signs
of haemorrhage in and around the tumour site were evi-
dent. After 48 h an eschar formed over the tumour site,
Fig. 1 T7 SCC tumours growing on the back of inbred female SKH1
mice were treated daily for two days with 0.25 % ingenol mebutate or
placebo gel. a Kaplan–Meier survival curves, with animals euthan-
ased when the tumour reached 100 mm2. b Growth curves of the
individual tumours described in a. The tumour sizes on day 0 were
Placebo group mean 10.8 ± SD 3.4 mm2 (range 4–17.5 mm2),
ingenol mebutate group 10.3 ± SD 2 mm2 (range 9–13.5 mm2)
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which resolved after 3–4 weeks, with a favourable
cosmetic outcome evident after 2–3 months (Fig. 2a).
Electron microscopy showed disruption of the inner
membrane and cristae of the tumour mitochondria within
hours of treatment, with complete loss of inner membrane
structures evident at 16–24 h (Fig. 2b). At 24 h post
treatment, primary necrosis of tumour cells was clearly
seen (Fig. 2b).
Histology of placebo-treated tumours (which were
indistinguishable from untreated tumours) illustrated their
subcutaneous location &200–300 lm below the epidermis
(Fig. 2c, left panel). Six hours after ingenol mebutate
treatment, widespread haemorrhage was evident through-
out the tumour (Fig. 2c, upper right panel) and the sur-
rounding tissue (not shown). A neutrophil infiltrate was
evident as early as 6 h post treatment (not shown), and by
Fig. 2 a Photographs of a T7
tumour site at various times post
treatment with ingenol
mebutate. Top row–pictures
taken of the skin in the intact
animal. Bottom row—pictures
taken of the excised tumour site,
with the skin turned over and
photographed from the dermal
side. b Electron micrographs.
Top row–tumour cell
mitochondria at the indicated
times post ingenol mebutate
treatment. Bottom left–T7
tumour cells after placebo
treatment. Bottom right–T7
tumour cells 24 h after placebo
treatment, showing clear signs
of primary necrosis. c H&E
staining of placebo treated
tumour (left) and high
magnification images of
haemorrhage within the tumour
6 h post ingenol mebutate
treatment (top right) and prolific
neutrophil infiltrates 24 h post
ingenol mebutate treatment
(bottom right)
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24 h prodigious neutrophil infiltrates were seen in and
around the tumour site (Fig. 2c, lower right panel).
Discussion
Herein, we show that ingenol mebutate gel treatment
(0.25 %) was effective at regressing subcutaneous SCCs
using the T7/SKH1 mouse model. This study, together with
previous clinical studies using E. peplus sap [14], supports
further clinical development of ingenol mebutate for the
treatment of SCCs in humans.
Ingenol mebutate gel treatment of SCCs in this model
resulted in a rapid onset of haemorrhage in and around the
tumour, disruption of tumour cell mitochondria and death
of the tumour cells by primary necrosis. A prodigious
infiltrate of neutrophils was observed, with post treatment
SCC-specific IgG responses also apparent (see Online
Resource 2), suggesting the activation of SCC-specific
CD4 T cells. These observations are consistent with pre-
vious studies using murine SCC lines grown in nude mice
and mouse B16 melanomas grown in C57/BL6 mice [4, 7,
9, 12], and support the view that ingenol mebutate gel
treatment kills tumour cells by inducing primary necrosis
with both the innate and adaptive immune systems being
activated.
The ingenol mebutate concentration in the gel (0.25 %)
required to cure T7 tumours was higher than the 0.05 %
being used to treat actinic keratoses in humans [8]; how-
ever, 0.25 % ingenol mebutate gel has been tested for the
treatment of superficial basal cell carcinomas in a small
number of patients [6]. LK2 tumours in nude mice were
effectively treated with 0.1 % ingenol mebutate given daily
for 3 days [4]. The reason for the lower dose requirement
in the LK2/nude model is unclear, with no overt differ-
ences in neutrophil infiltration apparent in the LK2/nude
and SKH1/T7 models. The LD90 values for in vitro treat-
ment of LK2 and T7 cells with ingenol mebutate were also
both &100 lg/ml (data not shown). The differences may
reflect increased drug penetration through nude mouse skin
[16] or other differences in skin biology, rather than be
related to immunological differences between the mouse
strains. The possible difference (p = 0.108) in cure rates
for male and female SKH1 mice may similarly reflect
increased drug penetration through female mouse skin [3].
Gender differences in the thickness of different skin layers
have been reported for SKH1 and other mice [1, 15], and in
our experience SKH1 male skin is tougher and harder to
inject than female skin. Such skin differences in mice may
influence drug penetration, but may also affect other factors
such as the consistency of shallow s.c. injections of tumour
cells and/or local dissemination of the tumours. It should
also be noted that there were no gender differences in the
efficacy of ingenol mebutate in the treatment of actinic
keratoses in humans [8].
Although SCCs are believed to be subject to immune
control [20], there is a paucity of SCC models in immu-
nologically intact mice [19]. We also investigated the 13.1
SCC line derived from C3H/HeN mice [11] and confirmed
its epithelial origin using electron microscopy (data not
shown). However, variable spontaneous regression rates
(0–60 %) and variable growth rates (10–60 days to reach
100 mm2) made this model difficult to use. In contrast, the
T7 SCC model provides a convenient and a reliable model
for testing interventions in immunologically intact mice;
however, the model does require an inbred SKH1 colony,
as these mice are no longer commercially available.
Acknowledgments This work was conducted with financial assis-
tance from Peplin Biotech Pty. Ltd. and a National Health and
Medical Research Industry Fellowship (S-J Cozzi). Peplin Inc is now
wholly owned by LEO Pharma.
Conflict of interest This work was conducted with financial assis-
tance from Peplin Biotech Pty. Ltd. and a National Health and
Medical Research Industry Fellowship (S-J Cozzi). Peplin Inc. is now
wholly owned by LEO Pharma. S-J Cozzi is now an employee of
LEO Pharma Inc., Australia. S Ogbourne is no longer an employee of
Peplin Biotech Pty. Ltd. A. Suhrbier has been a paid consultant for
Peplin Biotech Pty. Ltd. and LEO Pharma A/S.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Azzi L, El-Alfy M, Martel C et al (2005) Gender differences in
mouse skin morphology and specific effects of sex steroids and
dehydroepiandrosterone. J Invest Dermatol 124:22–27
2. Belkin D, Carucci JA (2011) Mohs surgery for squamous cell
carcinoma. Dermatol Clin 29:161–174
3. Bronaugh RL, Stewart RF, Congdon ER (1983) Differences in
permeability of rat skin related to sex and body site. J Soc Cosmet
Chem 34:127–135
4. Challacombe JM, Suhrbier A, Parsons PG et al (2006) Neutro-
phils are a key component of the antitumor efficacy of topical
chemotherapy with ingenol-3-angelate. J Immunol 177:8123–
8132
5. Cozzi SJ, Ogbourne SM, James C et al (2012) Ingenol mebutate
field-directed treatment of UVB-damaged skin reduces lesion
formation and removes mutant p53 patches. J Invest Dermatol
132:1263–1271
6. Ku J (2011) Clinical Review NDA 202833 PICATOTM. http://www.
accessdata.fda.gov/drugsatfda_docs/nda/2012/202833Orig1s000Me
dR.pdf.accessed May 2012
7. Le TT, Gardner J, Hoang-Le D et al (2009) Immunostimulatory
cancer chemotherapy using local ingenol-3-angelate and synergy
with immunotherapies. Vaccine 27:3053–3062
8. Lebwohl M, Swanson N, Anderson LL et al (2012) Ingenol
mebutate gel for actinic keratosis. N Engl J Med 366:1010–1019
82 Arch Dermatol Res (2013) 305:79–83
123
9. Li L, Shukla S, Lee A et al (2010) The skin cancer chemother-
apeutic agent ingenol-3-angelate (PEP005) is a substrate for the
epidermal multidrug transporter (ABCB1) and targets tumor
vasculature. Cancer Res 70:4509–4519
10. Love WE, Bernhard JD, Bordeaux JS (2009) Topical imiquimod
or fluorouracil therapy for basal and squamous cell carcinoma: a
systematic review. Arch Dermatol 145:1431–1438
11. Lucas AD, Halliday GM (1999) Progressor but not regressor skin
tumours inhibit Langerhans’ cell migration from epidermis to
local lymph nodes. Immunology 97:130–137
12. Ogbourne SM, Suhrbier A, Jones B et al (2004) Antitumor
activity of 3-ingenyl angelate: plasma membrane and mitochon-
drial disruption and necrotic cell death. Cancer Res 64:2833–
2839
13. Pelletier M, Maggi L, Micheletti A et al (2010) Evidence for a
cross-talk between human neutrophils and Th17 cells. Blood
115:335–343
14. Ramsay JR, Suhrbier A, Aylward JH et al (2011) The sap from
Euphorbia peplus is effective against human nonmelanoma skin
cancers. Br J Dermatol 164:633–636
15. Reeve VE, Allanson M, Domanski D et al (2012) Gender dif-
ferences in UV-induced inflammation and immunosuppression in
mice reveal male unresponsiveness to UVA radiation. Photochem
Photobiol Sci 11:173–179
16. Reifenrath WG, Chellquist EM, Shipwash EA et al (1984) Per-
cutaneous penetration in the hairless dog, weanling pig and
grafted athymic nude mouse: evaluation of models for predicting
skin penetration in man. Br J Dermatol 111(Suppl 27):123–135
17. Rosen RH, Gupta AK, Tyring SK (2012) Dual mechanism of
action of ingenol mebutate gel for topical treatment of actinic
keratoses: rapid lesion necrosis followed by lesion-specific
immune response. J Am Acad Dermatol 66:486–493
18. Smith E, von Vietinghoff S, Stark MA et al (2009) T-lineage cells
require the thymus but not VDJ recombination to produce IL-17A
and regulate granulopoiesis in vivo. J Immunol 183:5685–5693
19. Vahle AK, Kerem A, Ozturk E et al (2012) Optimization of an
orthotopic murine model of head and neck squamous cell carci-
noma in fully immunocompetent mice-role of Toll-like-receptor
4 expressed on host cells. Cancer Lett 317:199–206
20. Walter A, Barysch MJ, Behnke S et al (2010) Cancer-testis
antigens and immunosurveillance in human cutaneous squamous
cell and basal cell carcinomas. Clin Cancer Res 16:3562–3570
Arch Dermatol Res (2013) 305:79–83 83
123
